Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 820605, 5 pages
http://dx.doi.org/10.1155/2015/820605
Clinical Study

Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections

1Ophthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, Spain
2University of Zaragoza, Zaragoza, Spain

Received 2 December 2014; Revised 10 January 2015; Accepted 4 February 2015

Academic Editor: Caio V. Regatieri

Copyright © 2015 Pilar Calvo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodinamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57.e5–65.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study,” Ophthalmology, vol. 118, no. 5, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” The American Journal of Ophthalmology, vol. 143, no. 4, pp. 566–e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. F. G. Holz, W. Amoaku, J. Donate et al., “Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study,” Ophthalmology, vol. 118, no. 4, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. T. Holladay and T. C. Prager, “Snellen equivalent for the Bailey-Lovie acuity chart,” Archives of Ophthalmology, vol. 107, no. 7, p. 955, 1989. View at Google Scholar · View at Scopus
  9. C. A. Korb, U. B. Kottler, C. Wolfram et al., “Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 9, pp. 1403–1411, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. M. Brown, G. C. Brown, J. D. Stein, Z. Roth, J. Campanella, and G. R. Beauchamp, “Age-related macular degeneration: economic burden and value-based medicine analysis,” Canadian Journal of Ophthalmology, vol. 40, no. 3, pp. 277–287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Y. Wong, U. Chakravarthy, R. Klein et al., “The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis,” Ophthalmology, vol. 115, no. 1, pp. 116–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Rofagha, R. B. Bhisitkul, D. S. Boyer, S. R. Sadda, and K. Zhang, “Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP),” Ophthalmology, vol. 120, no. 11, pp. 2292–2299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Saleh, M. Kheliouen, E. Tebeanu et al., “Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 8, pp. 1901–1907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. F. Martin, M. G. Maguire, S. L. Fine et al., “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results,” Ophthalmology, vol. 119, no. 7, pp. 1388–1398, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Spaide, “Ranibizumab according to need: a treatment for age-related macular degeneration,” The American Journal of Ophthalmology, vol. 143, no. 4, pp. 679–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Engelbert, S. A. Zweifel, and K. B. Freund, “‘Treat and extend’ dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation,” Retina, vol. 29, no. 10, pp. 1424–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Engelbert, S. A. Zweifel, and K. B. Freund, “Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified ‘treat and extend’ dosing regimen of intravitreal antivascular endothelial growth factor therapy,” Retina, vol. 30, pp. 1368–1375, 2010. View at Google Scholar
  18. O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser, and C. D. Regillo, “A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact,” Ophthalmology, vol. 117, no. 11, pp. 2134–2140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. R. A. Mittra and J. S. Pollack, Preferences and Trends Membership Survey, American Society of Retina Specialists, Las Vegas, Nev, USA, 2012.